Hanmi Pharm announced on April it acquired a Korean patent related to a core technology of producing gemcitabine intermediate, entitled 1--halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative and its manufacturing method.
Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, and breast cancer. It is being investigated for use in esophageal cancer, and is us...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.